藥物釋放型支架市場－全球產業規模、佔有率、趨勢、機會、預測：按塗層類型、應用、地區和競爭格局分類，2021-2031年

全球藥物釋放型支架市場預計將從 2025 年的 83.7 億美元成長到 2031 年的 134.2 億美元，複合年成長率達到 8.19%。

藥物釋放型支架是一種塗覆有藥物的金屬網狀支架，植入狹窄的冠狀動脈中以維持通暢性並釋放藥物，從而預防血管再阻塞。推動這一市場成長的關鍵因素包括全球冠狀動脈疾病發生率的上升以及人口老化導致心血管併發症增加。此外，經皮冠狀動脈介入治療（PCI）的廣泛應用（PCI創傷性小於傳統外科繞道手術）也持續推動對這些血管內治療裝置的需求。

然而，嚴格的監管核准程序是市場成長的主要障礙，它推高了研發成本，並延緩了新技術的推出。製造商必須應對因地區而異的複雜合規體系，而且在新興市場，先進的治療方法往往難以獲得。根據歐洲心臟學會的數據，到2024年，高所得國家經皮冠狀動脈介入治療（PCI）的發生率將達到每百萬人2330例，這表明，儘管存在監管障礙，如此龐大的手術量仍在推動這些醫療設備的消費。

市場促進因素

生物可吸收和無聚合物支架的技術創新正在改變全球藥物釋放型支架市場，降低了與永久性金屬植入相關的長期安全風險。製造商正優先研發新一代支架，這些支架可在完全溶解前提供短暫的機械支撐和藥物釋放型，從而降低晚期血栓症的風險，並有助於恢復血管的自然舒縮功能。近期監管方面的成功也印證了這個趨勢。例如，雅培公司於2024年4月獲得FDA核准，其用於治療慢性下肢缺血的開創性可吸收支架——Esprit BTK依Everolimus洗脫可吸收支架系統——表明，治療方向正轉向無需永久性植入即可改善長期療效的器械。

冠狀動脈疾病盛行率的激增是人口結構變化的主要促進因素，導致全球介入治療的需求持續成長。隨著都市化和生活方式的改變，動脈粥狀硬化和心肌梗塞的發生率不斷上升，醫療系統正面臨著需要經皮冠狀動脈介入治療的患者數量急劇增加的局面。根據美國心臟協會 (AHA) 2024 年 1 月的報告，心血管疾病是 2021 年全球首要死因，造成約 1,991 萬人死亡。這一沉重的負擔為醫療設備製造商帶來了巨大的商機。Medtronic2024 年 5 月的財報顯示，其心血管產品組合的年收入達到 118.3 億美元，凸顯了該行業巨大的經濟規模，而這正是由持續的臨床需求所驅動的。

市場挑戰

嚴格的監管核准流程是全球藥物釋放型支架市場擴張的主要障礙。這些嚴格的合規要求直接增加了產品研發成本，並顯著延長了先進支架技術上市所需的時間。製造商必須應對不同國際司法管轄區複雜且往往不一致的要求，這常常導致新器械的商業化進程延誤。這些延誤限制了患者獲得先進治療方法的機會，阻礙了醫療設備製造商的產生收入，並最終造成瓶頸，限制了整體市場的成長。

這些監管延誤的影響已在近期行業績效指標中明顯反映。據歐洲醫療技術協會（MedTech Europe）稱，到2024年，根據新的醫療設備法規（MDR），醫療設備獲得認證的平均時間將延長至13-18個月，是先前法規下所需時間的兩倍。如此漫長的審查期迫使製造商將研發中的關鍵資源轉移到合規管理上，導致創新週期放緩，並減少進入全球藥物釋放型支架市場的新產品數量。

市場趨勢

目前，高安全性支架的研發和應用正成為一種策略趨勢，這類支架能夠顯著縮短雙聯抗血小板治療（DAPT）的療程，進而降低易感患者族群的出血風險。製造商正致力於獲得監管部門核准，將DAPT療程縮短至一個月，以應對長期抗凝血治療帶來嚴重風險的複雜病例的臨床管理挑戰。這種方法透過最佳化聚合物的生物相容性和藥物釋放動力學，實現早期停用抗血小板藥物，從而促進血管快速癒合。根據Terumo Corporation歐洲公司2025年3月發布的公告，高出血風險患者約佔所有經皮冠狀動脈介入治療（PCI）病例的45%，這凸顯了市場對既能確保安全又能縮短用藥療程的器械的迫切需求。

此外，製造商正在支架結構設計方面進行創新，例如採用超薄支架梁來提高柔軟性，並改善其在彎曲解剖結構中的放置。這些支架的支架梁厚度通常小於60微米，與較厚的支架相比，能夠促進內皮化和血管癒合，並有效減少血流阻塞和發炎。這種專注於先進結構導航的設計，正在全球範圍內獲得顯著的商業性勢頭，因為臨床醫生需要能夠在不犧牲徑向支撐力的情況下進入複雜病變部位的器械。根據微創醫療（MicroPort Scientific Corporation）2025年10月發布的新聞稿，該公司藥物釋放型支架的出貨量已達到1000萬件，2021年至2024年間，其國際銷售額的複合年成長率（CAGR）達到35%，凸顯了這些新一代介入技術的廣泛應用。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：藥物釋放型的全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 塗層類型（聚合物基塗層（不可生物分解、可生物分解）、無聚合物塗層（微孔表面、微結構表面、開槽管狀表面、奈米孔表面））
  • 依應用領域（冠狀動脈疾病、周邊動脈疾病）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美藥物釋放型支架市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲藥物釋放型支架市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區藥物釋放型支架市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲藥物釋放型支架市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美藥物釋放型支架市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球藥物釋放型支架市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Abbott Laboratories ltd.
• Boston Scientific Corporation
• Terumo Corporation
• Medtronic plc
• Biosensors International Ltd
• Cook Medical pvt ltd.
• B. Braun Medical（India）Private Limited
• Biotronik, Inc.
• Lepu Medical Technology Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Drug Eluting Stent Market is projected to expand from USD 8.37 Billion in 2025 to USD 13.42 Billion by 2031, achieving a compound annual growth rate of 8.19%. Defined as a metallic mesh scaffold coated with a pharmacological agent, a drug-eluting stent is deployed within a narrowed coronary artery to preserve vessel patency and release medication that prevents restenosis. Key drivers propelling this market growth include the rising global incidence of coronary artery disease and an aging population that is increasingly prone to cardiovascular complications. Additionally, the enduring clinical preference for minimally invasive percutaneous coronary interventions rather than traditional surgical bypass procedures continues to stimulate demand for these endovascular devices.

However, rigorous regulatory approval procedures pose a major obstacle that could hinder market growth by inflating development costs and stalling the launch of new technologies. Manufacturers must navigate intricate compliance frameworks that differ by region, often restricting immediate availability of advanced treatments in emerging markets. According to the European Society of Cardiology, in 2024, high-income nations recorded a percutaneous coronary intervention rate of 2,330 procedures per million people, highlighting the massive procedural volume that sustains the consumption of these medical devices despite the regulatory hurdles.

Market Driver

Technological innovations in bioabsorbable and polymer-free stents are transforming the Global Drug Eluting Stent Market by mitigating long-term safety risks linked to permanent metallic implants. Manufacturers are prioritizing next-generation scaffolds that offer temporary mechanical support and drug elution before fully dissolving, thereby lowering late-stage thrombosis risks and allowing natural vessel vasomotor function to return. This trend is illustrated by recent regulatory successes, such as Abbott's April 2024 announcement regarding FDA approval for the Esprit BTK Everolimus Eluting Resorbable Scaffold System, a pioneering dissolving stent for chronic limb-threatening ischemia, which signals a shift toward devices that enhance long-term outcomes without leaving permanent hardware.

The escalating prevalence of coronary artery disease acts as the primary demographic force driving market demand, requiring a continuous rise in interventional procedures worldwide. As urbanization and lifestyle shifts lead to increased rates of atherosclerosis and myocardial infarction, healthcare systems are experiencing a surge in patients needing percutaneous coronary interventions. According to the American Heart Association's January 2024 report, cardiovascular disease caused approximately 19.91 million deaths globally in 2021, cementing its status as the leading cause of mortality. This burden creates significant commercial prospects for device manufacturers, as evidenced by Medtronic's May 2024 financial report, which noted $11.83 billion in annual revenue from its Cardiovascular Portfolio, underscoring the sector's immense economic scale driven by these persistent clinical needs.

Market Challenge

Stringent regulatory approval processes represent a significant barrier to the expansion of the Global Drug Eluting Stent Market. These strict compliance frameworks directly inflate product development costs and considerably lengthen the timeline required to introduce advanced stenting technologies to the market. Because manufacturers must manage complex and often inconsistent requirements across various international jurisdictions, the commercial release of new devices is frequently delayed. Such delays limit patient access to enhanced therapies and impede revenue generation for medical device firms, effectively creating a bottleneck that suppresses the overall market growth trajectory.

The consequences of these regulatory delays are clearly reflected in recent industry performance metrics. According to MedTech Europe, the average time-to-certification for medical devices under the new Medical Device Regulation (MDR) extended to between 13 and 18 months in 2024, doubling the duration historically required under previous directives. These prolonged review periods compel manufacturers to reallocate essential resources toward compliance administration rather than research and development, consequently decelerating the innovation cycle and decreasing the volume of new products entering the Global Drug Eluting Stent Market.

Market Trends

A strategic trend is emerging toward the development and labeling of high-safety profile stents that permit significantly abbreviated Dual Antiplatelet Therapy (DAPT) regimens to mitigate bleeding risks in vulnerable patient groups. Manufacturers are focusing on obtaining regulatory approvals for one-month DAPT indications to resolve the clinical challenge of managing complex cases where long-term anticoagulation presents a serious danger. This approach involves optimizing polymer biocompatibility and drug release kinetics to facilitate rapid vessel healing, allowing for earlier cessation of antiplatelet drugs. According to a March 2025 announcement by Terumo Europe, patients at high risk of bleeding comprise roughly 45% of all PCI cases, emphasizing the urgent market demand for devices that ensure safety with shorter medication courses.

Additionally, manufacturers are increasingly innovating stent architecture by utilizing ultra-thin struts to enhance flexibility and improve deliverability within tortuous anatomy. These platforms, frequently engineered with strut thicknesses under 60 microns, promote faster endothelialization and vessel healing compared to thicker alternatives, effectively reducing flow disturbances and inflammation. This engineering focus on advanced structural navigability is generating significant commercial momentum globally as clinicians demand devices capable of accessing difficult lesions without sacrificing radial strength. According to MicroPort Scientific Corporation's October 2025 press release regarding its 10 million shipment milestone, international sales of its drug-eluting stents expanded at a compound annual growth rate of 35% between 2021 and 2024, highlighting the growing adoption of these next-generation interventional technologies.

Key Market Players

• Abbott Laboratories ltd.
• Boston Scientific Corporation
• Terumo Corporation
• Medtronic plc
• Biosensors International Ltd
• Cook Medical pvt ltd.
• B. Braun Medical (India) Private Limited
• Biotronik, Inc.
• Lepu Medical Technology Inc.

Report Scope

In this report, the Global Drug Eluting Stent Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Drug Eluting Stent Market, By Coating Type

• Polymer-based Coatings
• Polymer-free Coatings

Drug Eluting Stent Market, By Application

• Coronary Artery Disease
• Peripheral Artery Disease

Drug Eluting Stent Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Drug Eluting Stent Market.

Available Customizations:

Global Drug Eluting Stent Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Drug Eluting Stent Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Coating Type (Polymer-based Coatings (Non-biodegradable, Biodegradable)), Polymer-free Coatings(Micro porous Surface, Micro structured Surface, Slotted tubular Surface, Nanoporous Surface)
  • 5.2.2. By Application (Coronary Artery Disease, Peripheral Artery Disease)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Drug Eluting Stent Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Coating Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Drug Eluting Stent Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Coating Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Drug Eluting Stent Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Coating Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Drug Eluting Stent Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Coating Type
      • 6.3.3.2.2. By Application

7. Europe Drug Eluting Stent Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Coating Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Drug Eluting Stent Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Coating Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Drug Eluting Stent Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Coating Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Drug Eluting Stent Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Coating Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Drug Eluting Stent Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Coating Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Drug Eluting Stent Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Coating Type
      • 7.3.5.2.2. By Application

8. Asia Pacific Drug Eluting Stent Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Coating Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Drug Eluting Stent Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Coating Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Drug Eluting Stent Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Coating Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Drug Eluting Stent Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Coating Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Drug Eluting Stent Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Coating Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Drug Eluting Stent Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Coating Type
      • 8.3.5.2.2. By Application

9. Middle East & Africa Drug Eluting Stent Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Coating Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Drug Eluting Stent Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Coating Type
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Drug Eluting Stent Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Coating Type
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Drug Eluting Stent Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Coating Type
      • 9.3.3.2.2. By Application

10. South America Drug Eluting Stent Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Coating Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Drug Eluting Stent Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Coating Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Drug Eluting Stent Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Coating Type
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Drug Eluting Stent Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Coating Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Drug Eluting Stent Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbott Laboratories ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Boston Scientific Corporation
• 15.3. Terumo Corporation
• 15.4. Medtronic plc
• 15.5. Biosensors International Ltd
• 15.6. Cook Medical pvt ltd.
• 15.7. B. Braun Medical (India) Private Limited
• 15.8. Biotronik, Inc.
• 15.9. Lepu Medical Technology Inc.

16. Strategic Recommendations

17. About Us & Disclaimer